^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:Xpovio (selinexor) (XPO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Selinexor in Combination with Azacitidine (AZA) in Patients with Myelodysplastic Syndrome (MDS): A Real-World Retrospective Study

    Published date:
    11/02/2023
    Excerpt:
    Selinexor + AZA combination therapy was well tolerated with promising efficacy in patients with untreated or relapse/refractory MDS, including those with TP53 mutation, myelofibrosis, and higher risk in IPSS-R.
    Secondary therapy:
    azacitidine
    DOI:
    https://doi.org/10.1182/blood-2023-180626